NOVEL ribB

Abstract: The invention provides ribB polypeptides and polynucleotides encoding ribB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribB polypeptides to screen for antibacterial compounds.

Description: NOVEL ribB RELATED APPLICATIONS This application claims benefit of US Patent Application, Number 08/977.555. filed November 25, 1997 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides. and their production and uses, as well as their vanants, agonists and antagonists, and their uses In particular, the invention relates to novel polynucleotides and polypeptides of the Riboflavin synthase (α-subunit) family, hereinafter referred to as "nbB" BACKGROUND OF THE INVENTION The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia. meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrosprnal fluid Since its isolation more than 100 years ago Streptococcus pneumomae has been one of the more intensively studied microbes For example, much of our early understanding that DNA is, in fact, the genetic matenal was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe Despite the vast amount of research with S pneumomae, many questions concerning the virulence of this microbe remain It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics Riboflavin (vitamin B2) is a member of the B complex of vitamins which function as coenzymes in metabolic reactions Riboflavin has two coenzyme forms, flavm mononucleotide (FMN) and flavm adenme dinucleotide (FAD) which act m oxidation-reduction reactions such as the cytochrome system of electron transport and the oxidative degradation of pyruvate, fatty acids and amino acids The first committed step in the biosynthesis of riboflavin is the opening of the unidazole ring of GTP In the presence of 3 H2O and Mg ++ , the C-8 of GTP is released as formate accompanied by the release of pyrophosphate by the action of GTP cyclohyrolase II (GCH2. EC 3 5 4 25) This enzyme function is encoded by nbA in bacteria and nbl in yeast species Through a series of steps, involving 3,4-dιhydroxy-2-butanone 4 phosphate synthase (nbA), 6,7-dιmethyl-8-πbιtyllumazιne synthase (nbH). riboflavin synthase (ribB), pyπmidme deammase and pyπmidme reductase (nbG), enzymes encoded by genes within the nboflavm biosynthesis operon, riboflavin is formed Because the genes required for πboflavm biosynthesis are present m many pathogenic microorganisms, and since nboflavm biosynthesis has shown to be required for virulence in the swine pathogen Actmobacύlus pleuropneumomae (Fuller, TE. et al (1996) A riboflavin auxotroph of Actmobacύlus pleuropneumomae is attenuated in swme Infect Immun 64 4659-4664). these gene products represent broad spectrum antibacterial as well as anti ungal targets The frequency of Streptococcus pneumomae infections has nsen dramatically in the past few decades This has been attπbuted to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems It is no longer uncommon to isolate Streptococcus pneumomae strains which are resistant to some or all of the standard antibiotics This phenomenon has created a demand for both new anti-microbial agents, vaccmes, and diagnostic tests for this organism Clearly, there exists a need for factors, such as the πbB embodiments of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or conect such infection, dysfunction and disease Certain of the polypeptides of the invention possess ammo acid sequence homology to a known Actinobacύlus pleuropneumomae nbB protein See Swiss Prot Accession No P50854, GenBank Accession No U27202 Also see Perkins et al In Bacillus subtihs and Other Gram-Positive Bacteria Eds Sonenshein, AL, Hoch, JA and Losick, R 1993 American Society for Microbiology SUMMARY OF THE INVENTION It is an object of the invention to provide polypeptides that have been identified as novel nbB polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO 2 or 4] and a known amino acid sequence or sequences of other proteins such as Actinobαcύlus pleuropneumomae nbB protein It is a further object of the invention to provide polynucleotides that encode nbB polypeptides, particularly polynucleotides that encode the polypeptide herein designated nbB In a particularly prefened embodiment of the invention the polynucleotide compnses a region encoding nbB polypeptides compnsing a sequence set out in Table 1 [SEQ ED NO 1 or 3] which includes a full length gene, or a variant thereof In another particularly preferred embodiment of the mvention there is a novel nbB protein from Streptococcus pneumomae comprising the ammo acid sequence of Table 1 [SEQ ID NO 2 or 4], or a variant thereof A further aspect of the invention there are provided isolated nucleic acid molecules encodmg nbB, particularly Streptococcus pneumomae nbB, including mRNAs, cDNAs, genomic DNAs Further embodiments of the mvention include biologically, diagnostically, prophylactically. clinically or therapeutically useful vanants thereof, and compositions compnsing the same In accordance with another aspect of the mvention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization Among the particularly prefened embodiments of the mvention are naturally occurring allehc vanants of nbB and polypeptides encoded thereby Another aspect of the mvention there are provided novel polypeptides of Streptococcus pneumomae refened to herem as nbB as well as biologically, diagnostically. prophylactically, clinically or therapeutically useful vanants thereof, and compositions compnsmg the same Among the particularly prefened embodiments of the mvention are vanants of nbB polypeptide encoded by naturally occurring alleles of the nbB gene In a prefened embodiment of the mvention there are provided methods for producmg the aforementioned nbB polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, mcludmg, for example, antibodies In accordance with certain prefened embodiments of the mvention, there are provided products, compositions and methods for assessing nbB expression, treatmg disease, assaying genetic vanation, and administering a nbB polypeptide or polynucleotide to an organism to raise an lmmunological response against a bactena, especially a Streptococcus pneumomae bactena In accordance with certain prefened embodiments of this and other aspects of the mvention there are provided polynucleotides that hybndize to nbB polynucleotide sequences, particularly under stringent conditions In certain prefened embodiments of the mvention there are provided antibodies against nbB polypeptides In other embodiments of the mvention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the mvention compnsmg contactmg a polypeptide or polynucleotide of the mvention with a compound to be screened under conditions to permit binding to or other mteraction between the compound and the polypeptide or polynucleotide to assess the binding to or other mteraction with the compound, such binding or mteraction bemg associated with a second component capable of providing a detectable signal m response to the binding or mteraction of the polypeptide or polvnucleotide with the compound, and determinmg whether the compound bmds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detectmg the presence or absence of a signal generated from the binding or mteraction of the compound w th the polypeptide or polynucleotide In accordance with yet another aspect of the mvention, there are provided nbB agonists and antagonists, preferably bactenostatic or bactenocidal agonists and antagonists In a further aspect of the mvention there are provided compositions compnsing a nbB polynucleotide or a nbB polypeptide for administration to a cell or to a multicellular organism Vanous changes and modifications within the spmt and scope of the disclosed mvention will become readily apparent to those skilled m the art from reading the following descnptions and from reading the other parts of the present disclosure DESCRIPTION OF THE INVENTION The mvention relates to novel nbB polypeptides and polynucleotides as descnbed m greater detail below In particular, the mvention relates to polypeptides and polynucleotides of a novel nbB of Streptococcus pneumomae, which is related by ammo acid sequence homology to Actinobacillus pleuropneumomae nbB polypeptide The mvention relates especially to nbB having the nucleotide and ammo acid sequences set out m Table 1 as SEQ ID NO 1 and SEQ ID NO 2 respectively TABLE 1 ribB Polynucleotide and Polypeptide Sequences (A) Sequences from Streptococcus pneumoniae ribB polynucleotide sequence [SEQ ID NO:l]. 5 ' - ATGTTCACAGGAATAATTGAAGAAATCGGAAAAGTTGAAAGAATACAGAAAGACTCTCGTAATTGTAAA CTATCAATTAAAGCCTCAAAAATATTAACGGATATCCATTTAGGCGATAGTATAGCAGTAAATGGTATC TGTCTTACAGTTACTCATTTCAATCATCAATCCTTTACAGTTGATGTAATGAATGAAACATGGAGTCGA ACAGCTCTTACTCTATTAAAACATGGAAGTGAGGTGAATCTAGAAAGAGCCTTATCTGTCAACGGTCGA CTTGGGGGTCACGTCGTTACAGGACACATTGATGGTACAGGAAAAATCTCGTCAATAAAAAAAGATGAT AATGCTGTATGGTATCAAATCAACACACAAAAAGAAATTTTAGATTTAATAGTTGAAAAAGGATCTATT ACAATTGACGGCATTAGTCTGACTGTCGCTAAAGTCTCCAAAGTAAACTTTTCAGTATCTGTTATCCCT CATACCTTGAAACAAACCATTCTTAAGAGTAAACAAGTCGGGAGTACAGTAAATCTTGAAAATGATATC TTAGGTAA ATATGTGCAAAAACTGATGGATAACTCTCCAAAATCAGAAATATCGAAGGAACTATTATATCAAAATGG ATTTTAG- 3 ' (B) Streptococcus pneumoniae ribB polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:2]. NH 2 - MFTGIIEEIGJ VERIQKDSRNCKLSIKASKILTDIHLGDSIAVNGICLTVTHFNHQSFTVDλ NETWSR TALTLLKHGSEλ NLERALSV GRLGGHWTGHIDGTGKI S SI KKDDNAVWYQINTQKEILDLIVEKGS I TIDGISLTVAKVSKVNFSVSVIPHTLKQTILKSKQVGSTVNLENDILGK3A QKLMDNSPKSEISKELLY QNGF-COOH (C) Polynucleotide sequences comprising Streptococcus pneumoniae ribB ORF sequence [SEQ ID N0.3]. 5 ' - ATGTTCACAGGAATAATTGAAGAAATCGGAAAAGTTGAAAGAATACAGAAAGACTCTCGTAATTGTAAA CTATCAATTAAAGCCTCAAAAATATTAACGGATATCCATTTAGGCGATAGTATAGCAGTAAATGGTATC TGTCTTACAGTTACTCATTTCAATCATCAATCCTTTACAGTTGATGTAATGAATGAAACATGGAGTCGA ACAGCTCTCTTACTCTATTAAAACATGGAAGTGAGGTGAATCTAGAAAGAGCCTTATCTGTCAACGGTC GACTTGGGGGTCACGTCGTTACAGGACACATTGATGGTACAGGAAAAATCTCGTCAATAAAAAAAGATG ATAATGCTGTATGGTATCAAATCAACACACAAAAAGAAATTTTAGATTTAATAGTTGAAAAAGGATCTA TTACAATTGACGGCATTAGTCTGACTGTCGCTAAAGTCTCCAAAGTAAACTTTTCAGTATCTGTTATCC CTCATACCTTGAAACAAACCATTCTTAAGAGTAAACAAGTCGGGAGTACAGTAAATCTTGAAAATGATA TCTTAGGT AAATATGTGCAAAAACTGATGGATAACTCTCCAAAATCAGAAATATCGAAGGAACTATTATATCAAAAT GGATTTTAG-3' (D) Streptococcus pneumoniae nbB polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO 4] NH 2 - MFTGIIEEIGKVERIQKDSRNCKLSIKASKILTDIHLGDSIAVNGICLTVTHFNHQSFTVDVMNETWSR TALLLY -COOH Deposited materials A deposit containing a Streptococcus pneumomae 0100993 stram has been deposited with the National Collections of Industnal and Marine Bactena Ltd (herem "NCIMB"), 23 St Machar Dnve. Aberdeen AB2 1RY, Scotland on 11 Apnl 1996 and assigned deposit number 40794 The deposit was descnbed as Streptococcus peumnoiae 0100993 on deposit On 17 Apnl 1996 a Streptococcus peumnoiae 0100993 DNA library m E coli was similarly deposited with the NCIMB and assigned deposit number 40800 The Streptococcus pneumoniae stram deposit is refened to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited stram contams the full length nbB gene The sequence of the polynucleotides contained in the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any descnption of sequences herem The deposit of the deposited stram has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The stram will be inevocably and without restnction or condition released to the public upon the issuance of a patent The deposited strain is provided merely as convemence to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited stram, and compounds denved therefrom, and no such license is hereby granted One aspect of the mvention there is provided an isolated nucleic acid molecule encodmg a mature polypeptide expressible by the Streptococcus pneumoniae 0100993 stram contained the deposited stram Further provided by the mvention are nbB nucleotide sequences of the DNA m the deposited stram and ammo acid sequences encoded thereby Also provided by the mvention are nbB polypeptide sequences isolated from the deposited stram and ammo acid sequences denved therefrom Polypeptides The polypeptides of the mvention mclude a polypeptide of Table 1 [SEQ ID NO 2 or 4] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of nbB, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NO 1 or 3]or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NO 2 or 4and more preferably at least 90% similanty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and still more preferably at least 95% similanty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and also mclude portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the ammo terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R\ and R3 are any ammo acid residue, m is an mteger between 1 and 1000 or zero, n is an mteger between 1 and 1000 or zero, and R 2 is an ammo acid sequence of the mvention, particularly an ammo acid sequence selected from Table 1 In the formula above R 2 is onented so that its ammo terminal residue is at the left, bound to R j and its carboxy terminal residue is at the nght, bound to R3 Any stretch of ammo acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer A fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the ammo acid sequence of the aforementioned polypeptides As with nbB polypeptides fragments may be "free-standing," or compnsed within a larger polypeptide of which they form a part or region, most preferably as a smgle contmuous region, a smgle larger polypeptide Prefened fragments mclude, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NO 2 or 4], or of vanants thereof, such as a contmuous senes of residues that mcludes the ammo terminus, or a contmuous senes of residues that mcludes the carboxyl terminus Degradation forms of the polypeptides of the mvention m a host cell, particularly a Streptococcus pneumomae, are also prefened Further prefened are fragments characterized by structural or functional attributes such as fragments that compnse alpha-hehx and alpha-helix formmg regions, beta-sheet and beta-sheet-formmg regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic mdex regions Also prefened are biologically active fragments which are those fragments that mediate activities of nbB, mcludmg those with a similar activity or an improved activity, or with a decreased undesirable activity Also mcluded are those fragments that are antigenic or rmmunogemc m an animal, especially m a human Particularly preferred are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Streptococcus pneumoniae or the ability to initiate, or maintain cause disease m an individual, particularly a human Vanants that are fragments of the polypeptides of the mvention may be employed for producmg the conespondmg full-length polypeptide by peptide synthesis, therefore, these vanants may be employed as intermediates for producmg the full-length polypeptides of the mvention In addition to the standard smgle and triple letter representations for amino acids, the term "X" or "Xaa" may also be used in describing certain polypeptides of the mvention "X" and "Xaa" mean that any of the twenty naturally occurmg ammo acids may appear at such a designated position in the polypeptide sequence Polynucleotides Another aspect of the mvention relates to isolated polynucleotides, mcludmg the full length gene, that encode the nbB polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] and polynucleotides closely related thereto and vanants thereof Usmg the information provided herem, such as a polynucleotide sequence set out in Table 1 [SEQ ID NO 1 or 3]. a polynucleotide of the mvention encodmg nbB polypeptide may be obtained usmg standard cloning and screening methods, such as those for cloning and sequencmg chromosomal DNA fragments from bactena usmg Streptococcus pneumoniae 0100993 cells as starting matenal. followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the mvention, such as a sequence given in Table 1 [SEQ ID NO 1 or 3], typically a library of clones of chromosomal DNA f Streptococcus pneumoniae 0100993 in E coli or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, denved from a partial sequence Clones carrying DNA identical to that of the probe can then be distinguished usmg strmgent conditions By sequencing the individual clones thus identified with sequencmg primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence Convemently, such sequencmg is performed using denatured double stranded DNA prepared from a plasmid clone Suitable techmques are described by Ma atis, T , Fntsch, E F and Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989) (see m particular Screening By Hybndization 1 90 and Sequencmg Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention. the polynucleotide set out m Table 1 [SEQ ED NO 1 or 3] was discovered m a DNA library denved from Streptococcus pneumoniae 0100993 The DNA sequence set out m Table 1 [SEQ ID NO 1 or 3] contains an open reading frame encodmg a protem having about the number of ammo acid residues set forth rn Table 1 [SEQ ID NO 2 or 4] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known m the art The polynucleotide of SEQ ED NO 1. between nucleotide number 1 and the stop codon which begins at nucleotide number 634 of SEQ ID NO 1. encodes the polypeptide of SEQ ID NO 2 RibB of the mvention is structurally related to other protems of the Riboflavin synthase (α- subunit) family See Swiss Prot Accession No P50854, GenBank Accession No U27202 Also see Perkins et al In Bacillus subtihs and Other Gram-Positive Bacteria Eds Sonenshem, AL, Hoch, JA and Losick, R 1993 American Society for Microbiology The mvention provides a polynucleotide sequence identical over its entire length to a codmg sequence in Table 1 [SEQ ID NO 1 or 3] Also provided by the mvention is the codmg sequence for the mature polypeptide or a fragment thereof, by itself as well as the codmg sequence for the mature polypeptide or a fragment m reading frame with other codmg sequence, such as those encodmg a leader or secretory sequence, a pre-, or pro- or prepro- protem sequence The polynucleotide may also contain non-coding sequences, mcludmg for example, but not limited to non-coding 5' and 3' sequences, such as the transcnbed, non-translated sequences, termination signals, nbosome binding sites, sequences that stabilize mRNA, mtrons, polyadenylation signals, and additional codmg sequence which encode additional ammo acids For example, a marker sequence that facilitates punfication of the fused polypeptide can be encoded In certain embodiments of the mvention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc ) and descnbed in Gentz et al , Proc Natl Acad Sci , USA 86 821-824 (1989), or an HA tag (Wilson et al , Cell 37 767 (1984) Polynucleotides of the mvention also mclude, but are not limited to, polynucleotides compnsmg a structural gene and its naturally associated sequences that control gene expression A prefened embodiment of the mvention is a polynucleotide of compnsmg nucleotide 1 to the nucleotide immediately upstream of or mcludmg nucleotide 634 set forth m SEQ ID NO 1 of Table 1, both of which encode the nbB polypeptide The mvention also mcludes polynucleotides of the formula X-(R 1 ) m -(R 2 )-(R3)n-Y wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R\ and R3 is any nucleic acid residue, m is an mteger between 1 and 3000 or zero , n is an mteger between 1 and 3000 or zero, and R 2 is a nucleic acid sequence of the mvention, particularly a nucleic acid sequence selected from Table 1 In the polynucleotide formula above R 2 is onented so that its 5' end residue is at the left, bound to R\ and its 3' end residue is at the nght, bound to R3 Anv stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer In a prefened embodiment m and/or n is an mteger between 1 and 1000. It is most prefened that the polynucleotides of the inventions are denved from Streptococcus pneumoniae, however, they may preferably be obtamed from orgamsms of the same taxonomic genus They may also be obtamed. for example, from orgarusims of the same taxonomic family or order The term "polynucleotide encodmg a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encodmg a polypeptide of the mvention, particularly a bactenal polypeptide and more particularly a polypeptide of the Streptococcus pneumoniae nbB having an ammo acid sequence set out Table 1 [SEQ ID NO 2 or 4] The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encodmg the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain codmg and/or non-coding sequences The mvention further relates to vanants of the polynucleotides descnbed herem that encode for vanants of the polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ED NO 2 or 4] Vanants that are fragments of the polynucleotides of the mvention may be used to synthesize full- length polynucleotides of the mvention Further particularly prefened embodiments are polynucleotides encodmg nbB vanants, that have the ammo acid sequence of nbB polypeptide of Table 1 [SEQ ID NO 2 or 4] m which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, any combination Especially prefened among these are silent substitutions, additions and deletions, that do not alter the properties and activities of nbB Further prefened embodiments of the mvention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encodmg nbB polypeptide having an ammo acid sequence set out m Table 1 [SEQ ID NO 2 or 4]. and polynucleotides that are complementary to such polynucleotides Alternatively, most highly prefened are polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encodmg nbB polypeptide and polynucleotides complementary thereto In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly prefened, and among these particularly prefened pohnucleotides, those with at least 95% are especially prefened Furthermore, those with at least 97% are highly prefened among those with at least 95%. and among these those with at least 98% and at least 99% are particularly highly prefened, with at least 99% bemg the more prefened Prefened embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of Table 1 [SEQ ID NO 1 or 3] The mvention further relates to polynucleotides that hybndize to the herem above-descnbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stringent conditions to the herem above-descnbed polynucleotides As herem used, the terms "stringent conditions" and "stringent hybndization conditions" mean hybndization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of stringent hybridization conditions is overnight incubation at 42°C m a solution compnsmg 50% formamide, 5x SSC (150mM NaCl, 15mM tπsodium citrate), 50 mM sodium phosphate (pH7 6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0 lx SSC at about 65°C Hybridization and wash conditions are well known and exemplified in Sambrook, et al , Molecular Cloning A Laboratory Manual, Second Edition, Cold Spring Harbor, N Y , (1989), particularly Chapter 11 therem The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO 1 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO 1 or a fragment thereof, and isolating said DNA sequence Fragments useful for obtaining such a polynucleotide mclude. for example, probes and primers described elsewhere herem As discussed additionally herem regarding polynucleotide assays of the mvention, for instance, polynucleotides of the mvention as discussed above, may be used as a hybndization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encodmg nbB and to isolate cDNA and genomic clones of other genes that have a high sequence similanty to the nbB gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefened probes will have at least 30 bases and will have 0 bases or less For example, the codmg region of the nbB gene may be isolated by screening usmg a DNA sequence provided in Table 1 [SEQ ID NO 1 or 3] to synthesize an o gonucleotide probe A labeled ohgonucleotide having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herem relatmg to polynucleotide assays Polynucleotides of the invention that are oligonucleotides derived from the sequences of Table 1 [SEQ ID NOS 1 or 2 or 3 or 4] may be used in the processes herem as descnbed, but preferably for PCR, to determine whether or not the polynucleotides identified herem m whole or m part are transcribed m bacteria in infected tissue It is recognized that such sequences will also have utility m diagnosis of the stage of infection and type of infection the pathogen has attained The mvention also provides polynucleotides that may encode a polypeptide that is the mature protem plus additional ammo or carboxyl-termmal ammo acids, or ammo acids intenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance) Such sequences may play a role m processmg of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facilitate manipulation of a protem for assay or production, among other things As generally is the case in vivo, the additional ammo acids may be processed away from the mature protem by cellular enzymes A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an mactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proproterns In addition to the standard A, G, C, T/U representations for nucleic acid bases, the term "N" may also be used m descnbmg certain polynucleotides of the mvention "N" means that any of the four DNA or RNA bases may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a base that when taken m combmation with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon m such readmg frame In sum, a polynucleotide of the invention may encode a mature protein, a mature protem plus a leader sequence (which may be refened to as a preprotem) a precursor of a mature protem having one or more prosequences that are not the leader sequences of a preprotem. or a preproprotem which is a precursor to a proprotein. having a leader sequence and one or more prosequences. which generally are removed durmg processmg steps that produce active and mature forms of the polypeptide Vectors, host cells, expression The mvention also relates to vectors that compnse a polynucleotide or polynucleotides of the mvention, host cells that are genetically engineered with vectors of the mvention and the production of polypeptides of the mvention by recombinant techmques Cell-free translation systems can also be employed to produce such proteins usmg RNAs denved from the DNA constructs of the mvention For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the mvention Introduction of a polynucleotide mto the host cell can be effected by methods descnbed m many standard laboratory manuals, such as Davis et al, BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed . Cold Sprmg Harbor Laboratory Press, Cold Sprmg Harbor, N Y (1989), such as, calcium phosphate transfection. DEAE-dextran mediated transfection. transvection, micromjection, catiomc hpid- mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection Representative examples of appropnate hosts mclude bactenal cells, such as streptococci, staphylococci. enterococci E coli, streptomyces and Bacillus subtihs cells, fungal cells, such as yeast cells and Aspergillus cells, insect cells such as Drosophύa S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells, and plant cells A great vanety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude, among others, chromosomal, episomal and virus-denved vectors, e g , vectors denved from bactenal plasmids, from bactenophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses. fowl pox viruses, pseudorabies viruses and retrovrruses. and vectors denved from combinations thereof, such as those denved from plasmid and bactenophage genetic elements, such as cosmids and phagemids The expression system constructs may contam control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide m a host may be used for expression m this regard The appropnate DNA sequence may be inserted into the expression system by any of a vanety of well-known and rout e techmques. such as, for example, those set forth in Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra) For secretion of the translated protem mto the lumen of the endoplasmic reticulum, mto the penplasmic space or mto the extracellular environment, appropnate secretion signals may be incorporated mto the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and punfied from recombinant cell cultures by well-known methods mcludmg ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic mteraction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectm chromatography Most preferably, high performance liquid chromatography is employed for punfication Well known techmques for refoldmg protem may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or punfication Diagnostic Assays This mvention is also related to the use of the nbB polynucleotides of the mvention for use as diagnostic reagents Detection of nbB m a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease Eukaryotes (herem also "ιndrvιdual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compnsmg the nbB gene may be detected at the nucleic acid level by a vanety of techmques Nucleic acids for diagnosis may be obtamed from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin Genomic DNA may be used directly for detection or may be amplified enzymatically by usmg PCR or other amplification technique pnor to analysis RNA. cDNA and genomic DNA may also be used m the same ways Usmg amplification, charactenzation of the species and stram of prokaryote present m an mdividual. may be made by an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change m size of the amplified product m companson to the genotype of a reference sequence Pomt mutations can be identified by hybndizmg amphfied DNA to labeled nbB polynucleotide sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences m meltmg temperatures DNA sequence differences may also be detected by alterations m the electrophoretic mobility of the DNA fragments m gels, with or without denaturing agents, or by direct DNA sequencmg See, e g , Myers et al . Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method See, e g , Cotton et al , Proc Natl Acad Sci , USA, 85 4397-4401 (1985) Cells carrying mutations or polymorphisms m the gene of the mvention may also be detected at the DNA level by a vanety of techmques, to allow for serotyping, for example For example, RT- PCR can be used to detect mutations It is particularly prefened to used RT-PCR m conjunction with automated detection systems, such as, for example. GeneScan RNA, cDNA or genomic DNA may also be used for the same purpose, PCR or RT-PCR As an example, PCR primers complementary to a nucleic acid encodmg nbB can be used to identify and analyze mutations Examples of representative primers are shown below m Table 2 Table 2 Primers for amplification of ribB polynucleotides SEQ ID NO PRIMER SEQUENCE 5 5'-TCGGAAAAGTTGAAAGAATACAGA-3' 6 5 ' -TTACTTTGGAGACTTTAGCGACAG-3 ' The mvention also mcludes primers of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R\ and R3 is any nucleic acid residue, m is an mteger between 1 and 20 or zero , n is an mteger between 1 and 20 or zero, and R 2 is a primer sequence of the mvention, particularly a primer sequence selected from Table 2 In the polynucleotide formula above R 2 is onented so that its 5' end residue is at the left, bound to R^ and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer bemg complementary to a region of a polynucleotide of Table 1 In a prefened embodiment m and/or n is an mteger between 1 and 10. The mvention further provides these primers with 1. 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end These primers may be used for. among other things, amplifymg nbB DNA isolated from a sample denved from an individual The primers may be used to amplify' the gene isolated from an infected individual such that the gene may then be subject to vanous techmques for elucidation of the DNA sequence In this way. mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent The mvention further provides a process for diagnosing, disease, preferably bactenal infections, more preferably infections by Streptococcus pneumoniae, compnsmg determinmg from a sample denved from an individual a increased level of expression of polynucleotide having a sequence of Table 1 [SEQ ID NO 1 or 3] Increased or decreased expression of nbB polynucleotide can be measured usmg any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR- RNase protection. Northern blotting and other hybridization methods In addition, a diagnostic assay m accordance with the mvention for detecting over- expression of nbB protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techmques that can be used to determine levels of a nbB protein, m a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays Antibodies The polypeptides of the mvention or vanants thereof, or cells expressmg them can be used as an immunogen to produce antibodies lmmunospecific for such polypeptides "Antibodies" as used herem mcludes monoclonal and polyclonal antibodies, chimenc, smgle chain, simianized antibodies and humanized antibodies, as well as Fab fragments, mcludmg the products of an Fab -mmunolglobulin expression library Antibodies generated against the polypeptides of the mvention can be obtamed by admmistenng the polypeptides or epitope-beanng fragments, analogues or cells to an animal, preferably a nonhuman, usmg routme protocols For preparation of monoclonal antibodies, any technique known m the art that provides antibodies produced by contmuous cell line cultures can be used Examples mclude vanous techniques, such as those in Kohler, G and Milstein. C . Nature 256 495-497 (1975), Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77-96 m MONOCLONAL ANTIBODIES AND CANCER THERAPY. Alan R Liss, Inc (1985) Techmques for the production of smgle chain antibodies (U S Patent No 4.946.778) can be adapted to produce smgle chain antibodies to polypeptides of tins mvention Also, transgenic mice, or other orgamsms such as other mammals, may be used to express humanized antibodies Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amphfied v-genes of lymphocytes from humans screened for possessing anti-nbB or from naive hbranes (McCafferty, J et al , (1990), Nature 348, 552-554, Marks, J et al , (1992) Biotechnology 10, 779-783) The affinity of these antibodies can also be improved by chain shuffling (Clackson, T et al (1991) Nature 352, 624-628) If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressmg the polypeptides to punfy the polypeptides by affinity chromatography Thus, among others, antibodies against nbB- polypeptide may be employed to treat infections, particularly bactenal infections Polypeptide vanants mclude antigenically, epitopically or lmmunologically equivalent variants that form a particular aspect of this invention The term "antigenically equivalent denvative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protem or polypeptide accordmg to the mvention, interfere with the immediate physical interaction between pathogen and mammalian host The term "lmmunologically equivalent denvative" as used herein encompasses a peptide or its equivalent which when used m a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical mteraction between pathogen and mammalian host The polypeptide, such as an antigenically or lmmunologically equivalent derivative or a fusion protem thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken The fusion protem may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an lmmunogenic earner protem for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH) Alternatively a multiple antigenic peptide compnsmg multiple copies of the protein or polypeptide. or an antigenically or lmmunologically equivalent polypeptide thereof may be sufficiently antigenic to improve lmmunogenicity so as to obviate the use of a earner Preferably, the antibody or variant thereof is modified to make it less lmmunogenic in the individual For example, if the individual is human the antibody may most preferably be "humanized" where the comphmentaπty determining regιon(s) of the hybridoma-denved antibody has been transplanted into a human monoclonal antibody . for example as described in Jones, P et al (1986). Nature 321, 522-525 or Tempest et al , (1991) Biotechnology 9, 266-273 The use of a polynucleotide of the invention m genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA mto muscles (Wolff et al , Hum Mol Genet 1992, 1 363, Manthorpe et al , Hum Gene Ther 1963 4, 419), delivery of DNA complexed with specific protein carriers (Wu et al , J Biol Chem 1989 264,16985), coprecipitation of DNA with calcium phosphate (Benvemsty & Reshef, PNAS USA, 1986 83,9551), encapsulation of DNA in various forms of hposomes (Kaneda et al . Science 1989 243,375). particle bombardment (Tang et al , Nature 1992, 356 152, Eisenbraun et al , DNA Cell Biol 1993, 12 791) and in vivo infection using cloned retroviral vectors (Seeger et al , PNAS USA 1984 81,5849) Antagonists and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the binding of small molecule substrates and hgands m, for example, cells, cell-free preparations, chemical hbranes, and natural product mixtures These substrates and hgands may be natural substrates and hgands or may be structural or functional mimetics See, e g , Cohgan et al , Current Protocols in Immunology 1(2) Chapter 5 (1991) The mvention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of nbB polypeptides or polynucleotides, particularly those compounds that are bactenostatic and/or bactenocidal The method of screening may mvolve high-throughput techmques For example, to screen for agonists or antagoists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg nbB polypeptide and a labeled substrate or gand of such polypeptide is incubated m the absence or the presence of a candidate molecule that may be a nbB agomst or antagonist The ability of the candidate molecule to agonize or antagonize the nbB polypeptide is reflected m decreased binding of the labeled hgand or decreased production of product from such substrate Molecules that bmd gratuitously, i e . without mducmg the effects of nbB polypeptide are most likely to be good antagomsts Molecules that bmd well and mcrease the rate of product production from substrate are agomsts Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful m this regard mclude but are not limited to colonmetnc labeled substrate converted mto product, a reporter gene that is responsive to changes nbB polynucleotide or polypeptide activity, and binding assays known m the art Another example of an assay for nbB antagomsts is a competitive assay that combmes nbB and a potential antagonist with nbB-binding molecules, recombrnant nbB binding molecules, natural substrates or hgands, or substrate or hgand mimetics, under appropnate conditions for a competitive inhibition assay RibB can be labeled, such as by radioactivity or a colonmetnc compound, such that the number of nbB molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist Potential antagomsts mclude small orgamc molecules, peptides, polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagomsts also may be small orgamc molecules, a peptide, a polypeptide such as a closely related protem or antibody that bmds the same sites on a binding molecule, such as a binding molecule, without mducmg nbB-induced activities, thereby preventmg the action of nbB by excluding nbB from binding Potential antagomsts mclude a small molecule that bmds to and occupies the binding site of the polypeptide thereby preventmg binding to cellular binding molecules, such that normal biological activity is prevented Examples of small molecules mclude but are not limited to small orgamc molecules, peptides or peptide-like molecules Other potential antagomsts mclude antisense molecules (see Okano, J Neurochem 56 560 (1991), OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL (1988). for a descnption of these molecules) Prefened potential antagomsts mclude compounds related to and vanants of nbB Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds The encoded protem, upon expression, can be used as a target for the screemng of antibacterial drugs Additionally, the DNA sequences encodmg the ammo terminal regions of the encoded protem or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest The mvention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection In particular the molecules of the invention may be used m the prevention of adhesion of bacteria, m particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelhng devices or to extracellular matrix protems m wounds, to block nbB protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kmases (Rosenshme et al . Infect Immun 60 2211 (1992), to block bacterial adhesion between mammalian extracellular matrix protems and bactenal nbB protems that mediate tissue damage and, to block the normal progression of pathogenesis in infections imtiated other than by the implantation of in-dwellmg devices or bv other surgical techniques The antagomsts and agonists of the mvention may be employed, for instance, to inhibit and treat diseases Hehcobacter pylori (herem H pylori) bactena infect the stomachs of over one-third of the world's population causmg stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Hehcobacter Pylori (International Agency for Research on Cancer, Lyon, France, http //www uicc ch/ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H pylori and gastric adenocarcinoma, classifying the bactenum as a Group I (definite) carcinogen Prefened antimicrobial compounds of the invention (agonists and antagomsts of nbB) found using screens provided by the invention, particularly broad- spectrum antibiotics, should be useful in the treatment of H pylori infection Such treatment should decrease the advent of H /jy/oπ-induced cancers, such as gastrointestinal carcinoma Such treatment should also cure gastric ulcers and gastntis Vaccines Another aspect of the invention relates to a method for mducmg an immunological response m an individual, particularly a mammal which comprises inoculating the individual with nbB, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial mfection and most particularly Streptococcus pneumomae infection Also provided are methods whereby such immunological response slows bacterial replication Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of nbB. or a fragment or a variant thereof, for expressmg nbB. or a fragment or a variant thereof in vivo m order to induce an immunological response, such as. to produce antibody and or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established withm the individual or not One way of administering the gene is by acceleratmg it into the desired cells as a coating on particles or otherwise Such nucleic acid vector may comprise DNA. RNA, a modified nucleic acid, or a DNA/RNA hybnd A further aspect of the invention relates to an immunological composition which, when introduced mto an individual capable or having induced withm it an immunological response, induces an immunological response in such individual to a nbB or protem coded therefrom, wherein the composition comprises a recombmant nbB or protem coded therefrom compnsing DNA which codes for and expresses an antigen of said nbB or protem coded therefrom The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that ansmg from CTL or CD4+ T cells A nbB polypeptide or a fragment thereof may be fused with co-protem which may not by itself produce antibodies, but is capable of stabilizing the first protem and producmg a fused protem which will have lmmunogenic and protective properties Thus fused recombinant protem, preferably further comprises an antigenic co-protem, such as lrpoprotein D from Hemophilus mfluenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-protems which solubihze the protem and facilitate production and purification thereof Moreover, the co-protem may act as an adjuvant m the sense of providmg a generalized stimulation of the immune system The co-protem may be attached to either the ammo or carboxy terminus of the first protem Provided by this mvention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the mvention and immunostimulatory DNA sequences, such as those descnbed m Sato, Y et al Science 273 352 (1996) Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-vanable regions of bacterial cell surface protems in DNA constructs used in such genetic immunization experiments m ammal models of infection with Streptococcus pneumoniae will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the ammal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bactenal infection, particularly Streptococcus pneumoniae infection, m mammals, particularly humans The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue Examples of tissue damage mclude wounds m skin or connective tissue caused, e g , by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagma The invention also mcludes a vaccme formulation which comprises an lmmunogenic recombinant protem of the mvention together with a suitable carrier Smce the protem may be broken down in the stomach, it is preferably admimstered parenterally, mcludmg, for example, administration that is subcutaneous, intramuscular, intravenous, or lntradermal Formulations suitable for parenteral administration mclude aqueous and non-aqueous sterile injection solutions which may contam anti-oxidants, buffers, bactenostats and solutes which render the formulation lnsotomc with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous sterile suspensions which may include suspendmg agents or thickening agents The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dπed condition requiring only the addition of the sterile liquid carrier immediately prior to use The vaccme formulation may also mclude adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-m water systems and other systems known m the art The dosage will depend on the specific activity of the vaccme and can be readily determined by routine expenmentation While the mvention has been described with reference to certain nbB protem, it is to be understood that this covers fragments of the naturally occurrmg protem and similar protems with additions, deletions or substitutions which do not substantially affect the lmmunogenic properties of the recombinant protem Compositions, kits and administration The mvention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagomsts The polypeptides of the mvention may be employed m combmation with a non-stenle or stenle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for administration to a subject Such compositions compnse. for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof The formulation should suit the mode of administration The mvention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention may be employed alone or m conjunction with other compounds, such as therapeutic compounds The pharmaceutical compositions may be admimstered m any effective, convement manner mcludmg, for instance, administration by topical, oral, anal, vaginal, intravenous, mtrapentoneal, intramuscular, subcutaneous, rntranasal or mtradermal routes among others In therapy or as a prophylactic, the active agent may be admimstered to an individual as an mjectable composition, for example as a sterile aqueous dispersion, preferably lsotomc Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye omtments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contam appropnate conventional additives, mcludmg, for example, preservatives, solvents to assist drug penetration, and emollients in omtments and creams Such topical formulations may also contam compatible conventional carriers, for example cream or omtment bases, and ethanol or oleyl alcohol for lotions Such earners may constitute from about 1% to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg kg to 10 mg kg, typically around 1 mg/kg The physician m any event will determine the actual dosage which will be most suitable for an individual and will vary with the age. weight and response of the particular individual The above dosages are exemplar} of the average case There can, of course, be individual instances where higher or lower dosage ranges are mented, and such are withm the scope of this invention In-dw ellmg devices mclude surgical implants, prosthetic devices and catheters, l e . devices that are introduced to the body of an individual and remain in position for an extended time Such devices mclude. for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters cerebrospmal fluid shunts, urinary catheters, contmuous ambulatory peritoneal dialysis (CAPD) catheters The composition of the invention may be administered by injection to achieve a systemic effect agamst relevant bacteria shortly before insertion of an in-dwelling device Treatment may be contmued after surgery durmg the m-body time of the device In addition, the composition could also be used to broaden peπoperative cover for any surgical technique to prevent bactenal wound mfections. especially Streptococcus pneumoniae wound infections Mam orthopaedic surgeons consider that humans with prosthetic jomts should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep infection is a senous complication sometimes leadmg to loss of the prosthetic joint and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation In addition to the therapy described above, the compositions of this mvention may be used generalh as a wound treatment agent to prevent adhesion of bactena to matrix protems exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or m conjunction with, antibiotic prophylaxis Alternatively, the composition of the invention may be used to bathe an indwelling device lmmediatel} before insertion The active agent will preferably be present at a concentration of 1 μg/ml to 10 mg/ml for bathing of wounds or indwelling devices A vaccine composition is conveniently m mjectable form Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccmation is 0 5-5 microgram/kg of antigen, and such dose is preferably admimstered 1-3 times and with an interval of 1-3 weeks With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the mvention which would preclude their administration to suitable individuals Each reference disclosed herein is incorporated by reference herem in its entirety Any patent application to which this application claims priority is also incorporated by reference herein m its entirety GLOSSARY The following definitions are provided to facilitate understanding of certain terms used frequently herem "Dιsease(s)" means and disease caused by or related to infection by a bactena, mcludmg otitis media, conjunctivitis, pneumoma, bacteremia. menmgitis, smusitis, pleural empyema and endocarditis, and most particularly menmgitis, such as for example infection of cerebrospinal fluid "Host cell" is a cell which has been transformed or transfected. or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity," as known the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determmed by companng the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determmed by the match between strings of such sequences "Identity" and "similarity" can be readily calculated by known methods, mcludmg but not limited to those described in (Computational Molecular Biology, Lesk, A M , ed , Oxford Umversity Press, New York, 1988, Biocomputing Informatics and Genome Projects. Smith, D W . ed , Academic Press, New York, 1993, Computer Analysis of Sequence Data. Part I, Gnffin, A M . and Griffin, H G , eds , Humana Press, New Jersey, 1994, Sequence Analysis in Molecular Biology, von Hemje, G , Academic Press, 1987, and Sequence Analysis Primer, Gnbskov, M and Devereux, J , eds , M Stockton Press, New York, 1991, and Caπllo, H , and Lipman, D . SIAM J Applied Math , 48 1073 (1988) Preferred methods to determine identity are designed to give the largest match between the sequences tested Methods to determine identity and similarity are codified in publicly available computer programs Preferred computer program methods to determine identity and similanty between two sequences include, but are not limited to, the GCG program package (Devereux, J . et al , Nucleic Acids Research 12(1) 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S F et al , J Molec Biol 215 403-410 (1990) The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S , et al , NCBI NLM NIH Bethesda, MD 20894. Altschul, S , et al , J Mol Biol 215 403-410 (1990) As an illustration, by a polynucleotide havmg a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may mclude up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1 In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides m the reference sequence may be inserted into the reference sequence These mutations of the reference sequence may occur at the 5 " or 3 ' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, mterspersed either individually among nucleotides m the reference sequence or m one or more contiguous groups withm the reference sequence Analogously , by a polypeptide havmg an ammo acid sequence having at least, for example, 95% identity to a reference ammo acid sequence of SEQ ID NO 2 is intended that the ammo acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may mclude up to five ammo acid alterations per each 100 amino acids of the reference ammo acid of SEQ ID NO 2 In other words, to obtain a polypeptide havmg an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the ammo acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total ammo acid residues m the reference sequence may be inserted mto the reference sequence These alterations of the reference sequence may occur at the ammo or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, mterspersed either individually among residues m the reference sequence or in one or more contiguous groups withm the reference sequence "Isolated" means altered "by the hand of man" from its natural state, e , if it occurs in nature, it has been changed or removed from its ong nal environment, or both For example, a polynucleotide or a polypeptide naturally present m a Irving organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is "isolated", as the term is employed herem Moreover, a polynucleotide or polypeptide that is mtroduced mto an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be Irving or nonliving "Polynucleotιde(s)" generally refers to any polynbonucleotide or polydeoxnbonucleotide. which may be unmodified RNA or DNA or modified RNA or DNA "Polynucleotιde(s)" mclude, without limitation, smgle- and double-stranded DNA. DNA that is a mixture of smgle- and double- stranded regions or smgle-, double- and tnple-stranded regions, smgle- and double-stranded RNA and RNA that is mixture of smgle- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions. or a mixture of smgle- and double-stranded regions In addition, "polynucleotide" as used herem refers to tnple-stranded regions compnsmg RNA or DNA or both RNA and DNA The strands m such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically involve only a region of some of the molecules One of the molecules of a tnple-he cal region often is an ohgonucleotide As used herem, the term "polynucleotιde(s)" also mcludes DNAs or RNAs as descnbed above that contam one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotιde(s)" as that term is intended herem Moreover, DNAs or RNAs compnsmg unusual bases, such as inosine, or modified bases, such as tntylated bases, to name just two examples, are polynucleotides as the term is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art The term "polynucleotιde(s)" as it is employed herem embraces such chemically, enzymatically or metabohcally modified forms of polynucleotides, as well as the chemical forms of DNA and RNA charactenstic of viruses and cells, mcludmg, for example, simple and complex cells "Polynucleotιde(s)" also embraces short polynucleotides often refened to as ohgonucleotιde(s) "Polypeptιde(s)" refers to any peptide or protem compnsmg two or more ammo acids jomed to each other by peptide bonds or modified peptide bonds "Polypeptιde(s)" refers to both short chains, commonly refened to as peptides, ohgopeptides and ohgomers and to longer chains generally refened to as protems Polypeptides may contam ammo acids other than the 20 gene encoded ammo acids "Polypeptιde(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techmques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as m a voluminous research literature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present m the same or varying degree at several sites in a given polypeptide Also, a given polypeptide may contam many types of modifications Modifications can occur anywhere m a polypeptide, mcludmg the peptide backbone, the ammo acid side-chains and the ammo or carboxyl termini Modifications mclude, for example, acetylation. acylation, ADP-nbosylation. amidation, covalent attachment of flavm. covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide denvative covalent attachment of a lipid or hpid denvative, covalent attachment of phosphotidy nositol, cross-knking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteme. formation of pyroglutamate, formylation. gamma-carboxylation, glycosylation, GPI anchor formation, lodination, methylation, mynstoylation, oxidation, proteolytic processmg, phosphorylation, prenylatton, racemization. glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation, selenoylation, sulfation, transfer-RNA mediated addition of ammo acids to proteins, such as arginylatton. and ubiquitmatton See. for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed , T E Creighton. W H Freeman and Company, New York (1993) and Wold. F , Posttranslattonal Protem Modifications Perspectives and Prospects, pgs 1-12 POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B C Johnson, Ed , Academic Press, New York (1983), Serfter et al , Meth Enzymol 182 626-646 (1990) and Rattan et al , Protein Synthesis Posttranslattonal Modifications and Aging, Ann N Y Acad Sci 663 48- 62 (1992) Polypeptides may be branched or cyclic, with or without branching Cyclic, branched and branched circular polypeptides may result from post-translattonal natural processes and may be made by entirely synthetic methods, as well 'Nanant(s) " as the term is used herem, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical vanant of a polynucleotide differs m nucleotide sequence from another, reference polynucleotide Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result m ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below A typical vanant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference polypeptide and the vanant are closely similar overall and, in many regions, identical A vanant and reference polypeptide may differ m ammo acid sequence by one or more substitutions, additions, deletions m any combination A substituted or inserted amino acid residue may or may not be one encoded by the genetic code A variant of a polynucleotide or polypeptide may be a naturally occurnng such as an allelic variant, or it may be a variant that is not known to occur naturally Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans EXAMPLES The examples below are earned out usmg standard techmques, which are well known and routme to those of skill m the art, except where otherwise descnbed m detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The polynucleotide havmg a DNA sequence given m Table 1 [SEQ ID NO 1 or 3] was obtained from a library of clones of chromosomal DNA of Streptococcus pneumoniae in E coli The sequencmg data from two or more clones containing overlapping Streptococcus pneumoniae DNAs was used to construct the contiguous DNA sequence SEQ ID NO 1 Libranes may be prepared by routme methods, for example Methods 1 and 2 below Total cellular DNA is isolated from Streptococcus pneumoniae 0100993 accordmg to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size-fractionate accordmg to standard procedures DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added Fragments are hgated mto the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E coli infected with the packaged library The library is amphfied by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combmation of restriction enzymes appropriate to generate a series of fragments for cloning mto library vectors (e g , Rsal, Pall, Alul, Bshl235I). and such fragments are size-fractionated accordmg to standard procedures EcoRI linkers are hgated to the DNA and the fragments then hgated mto the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E coli mfected with the packaged library The library is amphfied by standard procedures Example 2 ribB Characterization A. Gene expression in vivo Recently several novel approaches have been described which purport to follow global gene expression dunng infection (Chuang, S et al , (1993), Mahan, M J et al , Science 259 686-688 (1993), Hensel, M et al , Science 269 400-403 (1995) These new techmques have so far been demonstrated with gram negative pathogen infections but not with infections with gram positives presumably because the much slower development of global transposon mutagenesis and suitable vectors needed for these strategies in these organisms, and m the case of that process described by Chuang, S et al , J Bacterwl 775 2026-2036 (1993) the difficulty of isolating suitable quantities of bacterial RNA free of mammalian RNA denved from the mfected tissue to furnish bacterial RNA labelled to sufficiently high specific activity The present mvention employs a novel technology to determine gene expression in the pathogen at different stages of infection of the mammalian host Use of the technology of the present invention enables identification of bactenal genes transcribed durmg infection, inhibitors of which would have utility m anti-bacterial therapy Specific inhibitors of such gene transcnption or of the subsequent translation of the resultant mRNA or of the function of the corresponding expressed protems would have utility m antibacterial therapy B. The determination of expression during infection of a gene from Streptococcus pneumoniae Lung tissue from a 48 hr pneumoma infection of Streptococcus pneumoniae #100993 m the mouse is efficiently disrupted and processed in the presence of acid phenol and detergent to provide a mixture of animal and bacterial RNA By freezing the tissue immediately m liquid nitrogen, and processmg the tissue samples while still frozen, changes in the population of bacterial mRNA is mimmized The resultant total RNA is free of DNA and protem (mcludmg RNAases and DNAases) The optimal conditions for disruption and processing to give high yields of bacterial mRNA with transcripts of long length are followed by reverse transcnbmg the resulting mRNA to cDNA and amphfied with ORF-specific primers for a bactenal gene known to be expressed constitutively and at low copy number Aspects of this example II. part b, are modifications of a published protocol (Cheung, et al , Anal Biochem ( 1994) 222 511- 514) a) Isolation of lung tissue infected with Streptococcus pneumomae #0100993 from a mouse respiratory tract infection model. Streptococcus pneumoniae #100993 was seeded onto TSA (Tryptic Soy Agar, BBL) plates containing 5% horse blood and allowed to grow overnight at 37°C in a C0 incubator Bacterial growth was scraped into 5 ml of phosphate- buffered saline (PBS) and adjusted to an Ag Q O ~ 0 6 (4 X 10 6 /ml) Mice (male CBA J-1 mice, approximately 20g) were anaesthetized with isoflurane and 50 microliters of the prepared bactenal inoculum was delivered by mtranasal instillation Animals were allowed to recover and observed twice daily for signs of moπbundancy Forty-eight hours after mfectton the animals were euthanized by carbon dioxide overdose and their torsos swabbed with ethanol and then RNAZap The torso was then opened, and the lungs were aseptically removed Half of each pair of lungs was placed m a cryovial and immediately frozen m liquid nitrogen, the other half was used for bactenal enumeration after homogemzatton of the tissue in 1 ml of PBS b) Isolation of Streptococcus pneumoniae #0100993 RNA from infected tissue samples. Infected tissue samples, in 2-ml cryo-strorage tubes, are removed from liquid nitrogen storage for immediate processmg of the frozen tissue In a microbiological safety cabinet the samples are disrupted up to eight at a time To disrupt the bacteria withm the tissue sample, 50-100 mg of the tissue is transfered to a FastRNA tube contaimng a silica/ceramic matrix (BIO 101) Immediately, 1 ml of extraction reagents (FastRNA reagents, BIO 101) are added to give a sample to reagent volume ratio of approximately 1 to 20 The tubes are shaken in a reciprocating shaker (FastPrep FP120, BIO101) ata setting of 5 5 to 6 for 20-120 sec The crude RNA preparation is extracted with chloroform isoamyl alcohol, and precipitated with DEPC-treated/Isopropanol Precipitation Solution (BIO 101) RNA preparations are stored in this isopropanol solution at -80°C if necessary The RNA is pelleted (12,000g for 10 mm ), washed with 75% ethanol (v/v m DEPC-treated water), air-dried for 5-10 mm, and resuspended m 0 1 ml of DEPC-treated water Quality of the RNA isolated is assessed by the ability to detect bacterial transcripts up to 2 kb in length by RT-PCR (as described below in section) To demonstrate the isolation of bacterial RNA from the mfected tissue, samples of RNA are reverse transcnbed, and the presence of a constituttvely expressed gene is detected through the use of quantitative PCR m the presence of a TaqMan probe (as described below) c) The removal of DNA from Streptococcus pneumoniae (0100993)-derived RNA. DNA was removed from 50 microgram samples of RNA by a 30 minute treatment at 37°C with 10 units of RNAase-free DNAasel (GeneHunter) in the buffer supplied in a final Λ olume of 57 microliters The DNAase was mactivated and removed by phenol chloroform extraction RNA was precipitated with 5 microliters of 3 M NaOAc and 200 microliters 100% EtOH, and pelleted by centrifugation at 12,000g for 10 minutes The RNA is pelleted (12,000g for 10 min ), washed with 75% ethanol (v/v m DEPC-treated water), air-dried for 5-10 mm, and resuspended in 10-20 microliters of DEPC-treated water RNA yield is quantitated by OD 2 gQ after 1 1000 dilution of the cleaned RNA sample RNA is stored at -80°C if necessary and reverse-transcribed withm one week d) The preparation of cDNA from RNA samples derived from infected tissue. 10 microliter samples of DNAase treated RNA are reverse transcribed using a SuperScnpt Preamphfication System for First Strand cDNA Synthesis kit (Gibco BRL, Life Technologies) accordmg to the manufacturers instructions 1 nanogram of random hexamers is used to pnme each reaction Controls without the addition of SuperScnptH reverse transcπptase are also run Both +/-RT samples are treated with RNaseH before proceeding to the PCR reaction e) The use of PCR to determine the quality of bacterial RNA derived from infected tissue. Long transcnpts, which are expected to be of low copy number withm the bacterial cell, such as penicilhn-b dmg protem 2 (PBP2). are reverse transcribed with random primers as described above and amphfied by the following PCR method usmg ORF-specific primers, m order to ascertain the quality, represented by length amplified, of the mRNA obtamed durmg extraction and punfication PCR reactions are set up on ice in 0 2 ml tubes in a total volume of 50 ul by addmg the following components [final concentration] AmpliTaq PCR Buffer II (IX). 1 5mM MgCL 2 1 mM dNTPs, 0 5uM forward primer. 0 5uM reverse primer, and 2 ul reverse-transcribed RNA PCR reactions are run on a PE GeneAmp PCR System 9600 with an initial step of 94°C for 2mm, followed by 35 cycles of 94 °C for 30sec, 42 °C for 30sec and 72 °C for 30sec, followed by a final extensison at 72 °C for 7mm f) The use of PCR to determine the presence of a bacterial cDNA species. PCR reactions are set up as described above using 0 5 microM each of the ORF specific forward and reverse primers PCR product in 20 microliter ahquots are separated by electrophoresis through 1 to 1 5% 1 x TBE agarose gels or 10% lx TBE acrylamide gels PCR product is visualized by staming the gel with ethidium bromide Size estimates are made by companson to a 100 bp DNA Ladder (Gibco BRL, Life Technologies) Alternatively, if the PCR products are conveniently labelled by the use of a labelled PCR primer (e g labelled at the 5 'end with a dye) a suitable aliquot of the PCR product is run out on a polyacrylamide sequencmg gel and its presence and quantity detected using a suitable gel scanning system (e g ABI 377 Sequencer usmg GeneScan software as supplied by Perkm Elmer) RT/PCR controls may mclude +/- reverse transcπptase reactions, 16s rRNA primers or DNA specific primer pairs designed to produce PCR products from non-transcnbed Streptococcus pneumoniae 0100993 genomic sequences To test the efficiency of the primer pairs they are used in DNA PCR with Streptococcus pneumoniae 0100993 total DNA PCR reactions are set up and run as described above usmg approx 1 microgram of DNA in place of the cDNA and 35 cycles of PCR Primer pairs which fail to give the predicted sized product in either DNA PCR or RT/PCR are PCR failures and as such are uninformative Of those which give the correct size product with DNA PCR two classes are distinguished in RT/PCR 1 Genes which are not transcribed in vivo reproducibly fail to give a product in RT/PCR, and 2 Genes which are transcribed in vivo reproducibly give the correct size product in RT/PCR and show a stronger signal in the +RT samples than the signal (if at all present) in -RT controls g) The use of PCR and fluorogenic probes to determine the presence of a bacterial cDNA species. Specific sequence detection occurs by amplification of target sequences in the PE Applied Biosystems 7700 Sequence Detection System m the presence of an ohgonucleotide probe labeled at the 5' and 3' ends with a reporter and quencher fluorescent dye, respectively (FQ probe), which anneals between the two PCR primers Only specific product will be detected when the probe is bound between the primers As PCR amplification proceeds, the 5 '-nuclease activity of Taq polymerase imtially cleaves the reporter dye from the probe The signal generated when the reporter dye is physically separated from the quencher dye is detected by measuring the signal with an attached CCD camera Each signal generated equals one probe cleaved which corresponds to amplification of one target strand PCR reactions are set up using the PE Applied Biosystem TaqMan PCR Core Reagent Kit according to the instructions supplied such that each reaction contains 5 microliters 1 OX PCR Buffer II 7 microliters 25 mM MgCl 2 , 5 microliters 300 nM forward primer, 5 microliters reverse primer. 5 microliters specific FQ probe. 1 microliter each 10 mM dATP, 10 mM dCTP, 10 mM dGTP and 20 mM dUTP, 13 25 microliters distilled water. 0 5 microliters AmpErase UNG, and 0 25 microliters AmpliTaq DNA polymerase to give a total volume of 45 microliters Amplification proceeds under the following thermal cycling conditions 50°C hold for 2 minutes, 95°C hold for 10 mmutes, 40 cycles of 95°C for 15 seconds and 60°C for 1 mmute, followed by a 25 °C hold until sample is retrieved Detection occurs real-time Data is collected at the end of the reaction Based on these analyses it was discovered that the Streptococcus pneumoniae nbB gene was transcribed in vivo C. Riboflavin Biosynthesis Operon This ORF is part of an operon which encodes genes nbG, ribB, rib A and nbH Gene nbG starts at nucleotide 1 and ends at nucleotide 1101 Gene nbB starts at nucleotide 1086 and ends at nucleotide 1721 Gene ribA starts at nucleotide 1711 and ends at nucleotide 2949 Gene nbH starts at nucleotide 2950 and ends at nucleotide 3417 The operon sequence [SEQ ID NO 7] follows ATGAGCGATTCAAAATATATGAAATTAGCAATAAAACTGGCACAAAAAGGGGCTGGTTACGTCAATCCC AATCCTATGGTTGGCGCAATTATTGTAAAAGATAATCACATTATCGGACAAGGTTATCATGAGTTTTTT GGTGGCCCACATGCTGAGAGAAATGCTCTTAAAAACTGTAGAAAATCCCCTGTCGGAGCGACGCTTTAT GTAACACTTGAACCCTGTTGTCACTTCGGGAAAACACCTCCCTGTATAGATGCTATAATCGATAGTGGT ATTACAAGAGTAGTCATTGGAAGCCTAGACTGTAATCCTATTGTATCTGGAAAAGGAGTAAAGATACTT GAGGAAAATAATCTTCAAGTTACTGTTGGAATTTTAGAAAATGAGTGTCTTAACTTAATAAAAAGTTTT AGAAAGTATATTACCCAGCATGTACCCTATGTTTTTATGAAATATGCAATGTCAATGGATGGAAAAATA GCCACTAAAACAAATCAATCCAAATGGATTACTGAAGAAGAAGCAAGAAAGCATGTGCATCAGTTACGA CACTATGTTAGTGCAATTATGGTGGGAGTCAATACTGTTATTCAAGACGATCCTTTGCTGACATGTAGA TTGGAGGAAGGGAAAAATCCTATCCGTATCATATGCGATACACATTTACGAACTCCTCTTACCTCTAAA ATCGTAAAAACAGCAAATGATATTAAAACTTACATTGCCACTTCCTCTGAAGACAAAAATAAAATGAAG CTATATCAAAATCATGGCTGTGAAATACTTTCCATAAAGAAAAAAGGCAATCATATAGACTTATCGAGT TTAATGCAACATCTAGGAAACATGCAGATTGATAGCCTAGTTCTAGAGGGGGGCAGTCTAATGAATTGG AGTGCTTTGGAACAACAAATTGTTGATGAGCTGAAAATATATATTGCACCAAAAATTTTTGGAGGCAGT GCCAAGTTTCCTGTCGGAGGTGAAGGCATTTCTTTGCCAAATGACGCTATTAGATTGAAACCTTATGCT TTTTCTCAAATAGGAAATGACTATCTCATAGAAAGTGAAGTGATTTATCCATGTTCACAGGAATAATTG AAGAAATCGGAAAAGTTGAAAGAATACAGAAAGACTCTCGTAATTGTAAACTATCAATTAAAGCCTCAA AAATATTAACGGATATCCATTTAGGCGATAGTATAGCAGTAAATGGTATCTGTCTTACAGTTACTCATT TCAATCATCAATCCTTTACAGTTGATGTAATGAATGAAACATGGAGTCGAACAGCTCTTACTCTATTAA AACATGGAAGTGAGGTGAATCTAGAAAGAGCCTTATCTGTCAACGGTCGACTTGGGGGTCACGTCGTTA CAGGACACATTGATGGTACAGGAAAAATCTCGTCAATAAAAAAAGATGATAATGCTGTATGGTATCAAA TCAACACACAAAAAGAAATTTTAGATTTAATAGTTGAAAAAGGATCTATTACAATTGACGGCATTAGTC TGACTGTCGCTAAAGTCTCCAAAGTAAACTTTTCAGTATCTGTTATCCCTCATACCTTGAAACAAACCA TTCTTAAGAGTAAACAAGTCGGGAGTACAGTAAATCTTGAAAATGATATCTTAGGTAAATATGTGCAAA AACTGATGGATAACTCTCCAAAATCAGAAATATCGAAGGAACTATTATATCAAAATGGATTTTAGCAGA AAGGATAATCAGTCAATGGAATATCGAAAAATGACAAGAAGCATTGAGGAAGCATTGCAGAAGGGACGA CTTGTTCTTGTTATAGACGACAAGGATAGAGAAAATGAAGGAGACTTAATTTGTTCTGCACAAGCAGCT ACAACAGAAAATGTTAATTTTATGGCTACTTATGCCAAAGGATTAATTTGTATGCCTATGAGCGAAAGT TTAGCTAATCAATTAATGCTTTCACCTATGGTTGAAAACAATACAGATAATCATAAGACTGCTTTTACA GTTTCAATTGATTATAAAGAAACGACCACAGGTATTTCTGCCGAGGAAAGAGGACTGACCGCACGTATG TGTGTAGCTGAAGATATAACACCCTCTGATTTTCGCAGGCCAGGACACATGTTTCCTTTAATTGCAAAA AAAGGTGGTGTTCTAGAAAGAAATGGACACACAGAAGCAACTGTTGATTTATTAAAATTAGCTGGACTA AAAGAGTGTGGCCTATGTTGTGAAATAATGAATCATGATGGCAAAATGATGAGAACAGATGATTTAATT CAGTTCTCGAAGAAACACAACATTCCACTAATTACCATCAAAGAATTACAAGAATATAGAAAAGTATAT GATCAGCTGGTAGAACGAGTTTCAACTGTCAATATGCCTACTAGATACGGTAATTTCAAAGCAATTAGC TATATAGATAAACTAAATGGGGAACATCATCTTGCTCTTATTATGGGAAACATAGAGGATGAAGCCAAT GTATTATGTCGGGTCCACTCCGAATGTTTAACAGGAGATGTTTTAGGCTCTTTACGTTGCGATTGTGGA CAGCAATTCGATAAAGCTATGAAAATGATTGTTGAGAATGGTTCGGGTGTCTTACTTTACTTGCGACAG GAGGGACAAGGAATTGGACTTATCAATAAATTAAAAGCCTATCATTTACAAAATCAAGGCATGGATACG CTTGATGCCAATCTTGCATTAGGCTTTGAAGGTGATTTAAGAGAATATCATATTGGAGCACAAATGCTT AAAGATCTGGGACTTCAGTCACTTCATTTACTGACAAATAATCCTGACAAGGTTGAACAGTTAGAAAAA TATGGAATTACCATTTCCAGTAGAATATCAATCGAAATAGAAGCCAATCCTTACGATAGTTTTTATTTA GAAACAAAGAAAAATCGAATGGGTCACATTTTAAATATGGAGGAAAAATAAATGAACACTTATGAAGGT AATTTAGTAGCAAACAATATTAAAATAGGTATTGTTGTAGCGAGATTTAATGAATTTATAACTTCAAAA TTATTATCTGGAGCACTAGATAATCTCAAAAGAGAGAATGTAAACGAGAAAGATATCGAGGTAGCCTGG GTTCCAGGAGCTTTTGAAATACCACTGATTGCATCAAAAATGGCAAAAAGTAAAAAATATGATGCAATT ATCTGCTTGGGAGCTGTCATTAGAGGGAATACAAGTCATTATGATTATGTATGTAGCGAGGTATCTAAA GGAATCGCCCAAATCAGTTTAAATAGCGAAATTCCTGTTATGTTTGGTGTGCTAACGACAGATACAATT GAACAAGCCATAGAACGAGCTGGTACTAAAGCAGGAAATAAGGGTTCTGAGTGTGCACAAGGAGCTATT GAAATGGTCAACCTAATTCGTACATTAGACGCATAG [SEQ ID NO: 7]

Claims: What is claimed is: 1 An isolated polynucleotide compnsmg a polynucleotide having at least a 70% identity to a polynucleotide encodmg a polypepttde compnsmg the ammo acid sequence of SEQ ID NO 2 2 An isolated polynucleotide compnsmg a polynucleotide at least a 70% identity to a polynucleotide encodmg the same mature polypeptide expressed by the nbB gene contained m the Streptococcus pneumoniae of the deposited stram 3 An isolated polynucleotide compnsmg a polynucleotide encodmg a polypepttde compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 4 An isolated polynucleotide that is complementary to the polynucleotide of claim 1 5 The polynucleotide of Claim 1 wherem the polynucleotide is DNA or RNA 6 The polynucleotide of Claim 1 compnsmg the nucleic acid sequence set forth m SEQ ID NO 1 7 The polynucleotide of Claim 1 compnsmg nucleotide 1 to the stop codon which begins at nucleotide number 634 set forth m SEQ ID NO 1 8 The polynucleotide of Claim 1 which encodes a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 9 A vector compnsmg the polynucleotide of Claim 1 10 A host cell compnsmg the vector of Claim 9 11 A process for producmg a polypepttde compnsmg expressmg from the host cell of Claim 10 a polypepttde encoded by said DNA 12 A process for producmg a nbB polypeptide or fragment compnsing cultunng a host of claim 10 under conditions sufficient for the production of said polypepttde or fragment 13 A polypepttde compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 14 A polypeptide compnsmg an ammo acid sequence as set forth SEQ ID NO 2 15 An antibody against the polypepttde of claim 14 16 An antagonist which inhibits the activity or expression of the polypepttde of claim 14 17 A method for the treatment of an individual m need of nbB polypepttde compnsmg admmistenng to the individual a therapeutically effective amount of the polypeptide of claim 14 18 A method for the treatment of an mdividual havmg need to inhibit nbB polypepttde compnsmg admmistenng to the mdividual a therapeutically effective amount of the antagomst of Claim 14 19 A process for diagnosing a disease related to expression or activity of the polypepttde of claim 14 an mdividual compnsmg (a) determining a nucleic acid sequence encodmg said polypeptide, and/or (b) analyzing for the presence or amount of said polypeptide m a sample denved from the mdividual 20 A method for identifying compounds which mteract with and inhibit or activate an activity of the polypepttde of claim 14 compnsmg contactmg a composition compnsmg the polypeptide with the compound to be screened under conditions to permit mteraction between the compound and the polypepttde to assess the mteraction of a compound, such mteraction bemg associated with a second component capable of providing a detectable signal response to the mteraction of the polypeptide with the compound, and determinmg whether the compound interacts with and activates or inhibits an activity of the polypepttde by detectmg the presence or absence of a signal generated from the mteraction of the compound with the polypepttde 21 A method for mducmg an immunological response in a mammal which compnses inoculating the mammal with nbB polypepttde of claim 14, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease 22 A method of mducmg immunological response m a mammal which comprises delivering a nucleic acid vector to direct expression of nbB polypepttde of claim 14, or fragment or a variant thereof, for expressmg said nbB polypeptide, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease 23 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 4 24 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to the polynucleotide sequence of SEQ ID NO 3

Inventors: BLACK MICHAEL T, FEDON JASON C, HODGSON JOHN E, KNOWLES DAVID J C, KOSMATKA ANNA L, LONETTO MICHAEL A, NICHOLAS RICHARD O, PALMER LESLIE M, SHILLING LISA K, STODOLA ROBERT K, WARREN RICHARD L, BLACK, MICHAEL, T., FEDON, JASON, C., HODGSON, JOHN, E., KNOWLES, DAVID, J., C., KOSMATKA, ANNA, L., LONETTO, MICHAEL, A., NICHOLAS, RICHARD, O., PALMER, LESLIE, M., SHILLING, LISA, K., STODOLA, ROBERT, K., WARREN, RICHARD, L.
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: C12P21
IPC codes: A61K31, A61K38, A61K39, A61K45, A61K48, A61P29, A61P31, A61P37, C07K14, C07K16, C12N1, C12N9, C12N15, C12P21, G01N33